FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895886788> ?p ?o ?g. }

• W2895886788 endingPage "20180422" @default.
• W2895886788 startingPage "20180422" @default.
• W2895886788 abstract "A multiarm Phase I clinical trial was performed to define the maximum tolerated dose (MTD) of stereotactic body radiotherapy (SBRT) delivered by non-coplanar conformal beams or volumetric modulated arc therapy technique in seven predefined clinical settings.The (a) and (b) arms investigated primary and metastatic lung cancer differentiated by site of onset, arm (c) included primary or metastatic lesions outside the thorax, the (d) and (e) arms were for in-field reirradiation of recurrence, and finally, the (f) and (g) arms were for boost irradiation to the lesions after an adjuvant RT prescribed dose. A 4 months cut-off after previous irradiation course was fixed to distinguish the boost from the retreatment (<4 vs >4 months, respectively). Patients were prospectively enrolled in study arms according to tumor site, clinical stage and previous treatment. The total dose prescribed to the isocenter, ranged from 20 to 50 Gy according to the protocol design and the doses per fraction ranged from 4 to 10 Gy in 5 days.A total of 281 patients (M/F: 167/114; median age: 69 years) with 376 lesions underwent SBRT. No acute toxicity was reported in 175 patients (62.3%) while 106 (37.7%) experienced only low-grade (G < 2) acute toxicity. Four patients (all previously irradiated in the same site) showed >Grade 2 toxicity within 6 months from SBRT. With a median follow-up of 19 months, 204 patients (72.6%) did not experience late toxicity, and 77 (27.4%) experienced low grade late toxicity. On per-lesion basis, the 12-and 24 months actuarial local control inside the SBRT field were 84.3 and 73.7 %, respectively.SBRT delivered in five consecutive fractions up to the doses evaluated is well tolerated. The MTD was reached in four (a, b, c and f) of the seven study arms. Recruitment for (d), (e) and (g) arms is still ongoing.In a prospective dose-escalation trial, the MTD of 50 Gy/10 Gy fraction and 35 Gy/7 Gy fraction were defined for primary and metastatic lesions and as boost after prior RT dose ≤50 Gy, respectively." @default.
• W2895886788 created "2018-10-26" @default.
• W2895886788 creator A5000531166 @default.
• W2895886788 creator A5008208200 @default.
• W2895886788 creator A5030819607 @default.
• W2895886788 creator A5038579623 @default.
• W2895886788 creator A5049406967 @default.
• W2895886788 creator A5051494397 @default.
• W2895886788 creator A5052778814 @default.
• W2895886788 creator A5056652700 @default.
• W2895886788 creator A5070096760 @default.
• W2895886788 creator A5072142019 @default.
• W2895886788 date "2019-02-01" @default.
• W2895886788 modified "2023-10-02" @default.
• W2895886788 title "Dose escalation in extracranial stereotactic ablative radiotherapy (DESTROY-1): A multiarm Phase I trial" @default.
• W2895886788 cites W1973249355 @default.
• W2895886788 cites W1973888786 @default.
• W2895886788 cites W1979485825 @default.
• W2895886788 cites W1982836714 @default.
• W2895886788 cites W1989995039 @default.
• W2895886788 cites W2005917399 @default.
• W2895886788 cites W2015107633 @default.
• W2895886788 cites W2036855640 @default.
• W2895886788 cites W2043945205 @default.
• W2895886788 cites W2044990567 @default.
• W2895886788 cites W2050957719 @default.
• W2895886788 cites W2061653825 @default.
• W2895886788 cites W2061727880 @default.
• W2895886788 cites W2068179902 @default.
• W2895886788 cites W2069976078 @default.
• W2895886788 cites W2085278478 @default.
• W2895886788 cites W2088901883 @default.
• W2895886788 cites W2092656034 @default.
• W2895886788 cites W2100699934 @default.
• W2895886788 cites W2106389680 @default.
• W2895886788 cites W2107814019 @default.
• W2895886788 cites W2108549165 @default.
• W2895886788 cites W2132764039 @default.
• W2895886788 cites W2135374201 @default.
• W2895886788 cites W2136706275 @default.
• W2895886788 cites W2139248078 @default.
• W2895886788 cites W2149959537 @default.
• W2895886788 cites W2154999931 @default.
• W2895886788 cites W2155070439 @default.
• W2895886788 cites W2159746573 @default.
• W2895886788 cites W2162427240 @default.
• W2895886788 cites W2165322374 @default.
• W2895886788 cites W2179010101 @default.
• W2895886788 cites W2297382265 @default.
• W2895886788 cites W2345091740 @default.
• W2895886788 cites W2466358553 @default.
• W2895886788 cites W2472758189 @default.
• W2895886788 cites W2494058136 @default.
• W2895886788 cites W2545316720 @default.
• W2895886788 cites W2621684067 @default.
• W2895886788 cites W2754041892 @default.
• W2895886788 cites W4237765593 @default.
• W2895886788 cites W4240340450 @default.
• W2895886788 cites W4293241248 @default.
• W2895886788 doi "https://doi.org/10.1259/bjr.20180422" @default.
• W2895886788 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6404833" @default.
• W2895886788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30325662" @default.
• W2895886788 hasPublicationYear "2019" @default.
• W2895886788 type Work @default.
• W2895886788 sameAs 2895886788 @default.
• W2895886788 citedByCount "8" @default.
• W2895886788 countsByYear W28958867882019 @default.
• W2895886788 countsByYear W28958867882020 @default.
• W2895886788 countsByYear W28958867882021 @default.
• W2895886788 countsByYear W28958867882022 @default.
• W2895886788 countsByYear W28958867882023 @default.
• W2895886788 crossrefType "journal-article" @default.
• W2895886788 hasAuthorship W2895886788A5000531166 @default.
• W2895886788 hasAuthorship W2895886788A5008208200 @default.
• W2895886788 hasAuthorship W2895886788A5030819607 @default.
• W2895886788 hasAuthorship W2895886788A5038579623 @default.
• W2895886788 hasAuthorship W2895886788A5049406967 @default.
• W2895886788 hasAuthorship W2895886788A5051494397 @default.
• W2895886788 hasAuthorship W2895886788A5052778814 @default.
• W2895886788 hasAuthorship W2895886788A5056652700 @default.
• W2895886788 hasAuthorship W2895886788A5070096760 @default.
• W2895886788 hasAuthorship W2895886788A5072142019 @default.
• W2895886788 hasBestOaLocation W28958867882 @default.
• W2895886788 hasConcept C116263406 @default.
• W2895886788 hasConcept C126322002 @default.
• W2895886788 hasConcept C126838900 @default.
• W2895886788 hasConcept C126894567 @default.
• W2895886788 hasConcept C141071460 @default.
• W2895886788 hasConcept C181401712 @default.
• W2895886788 hasConcept C2781156865 @default.
• W2895886788 hasConcept C29730261 @default.
• W2895886788 hasConcept C2989005 @default.
• W2895886788 hasConcept C509974204 @default.
• W2895886788 hasConcept C71924100 @default.
• W2895886788 hasConceptScore W2895886788C116263406 @default.
• W2895886788 hasConceptScore W2895886788C126322002 @default.
• W2895886788 hasConceptScore W2895886788C126838900 @default.
• W2895886788 hasConceptScore W2895886788C126894567 @default.

• next